Expanding the possibilities of using sodium-glucose cotransporter 2 inhibitors in patients with heart failure

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Postpartum infections (n=21968). Primary outcome: Prevalence of postpartum infection (95% CI 27.8-28.4).

Q: What does this research mean for the field?

Postpartum infections occurred in 28.1% of women following vaginal delivery or cesarean section in Ukraine, with 83.1% of these infections detected after hospital discharge. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Мaryana М. Rоsul; Мyroslava М. Bletskan; Nataliya V. Ivano; Svitlana O. Rudakova

doi:10.36740/wlek202403130

January 1, 2024Wiadomości Lekarskie

Expanding the possibilities of using sodium-glucose cotransporter 2 inhibitors in patients with heart failure

View Full Paper

Ask AI

Bookmark

Share

Why the study?

To examine the potential cardiovascular mechanisms of SGLT-2 inhibitors and the possibilities of improving treatment and prognosis in acute heart failure.

Study Design

Type

Cohort (n=21,968)

Multicenter

Yes

Structured PICO

P

Population

21,968 women who had a vaginal delivery (n=17,768) or cesarean section (n=4,200) from January 1, 2020, to December 31, 2022, and who received postpartum care at 15 hospitals from 12 regions of Ukraine.

O

Outcome

Prevalence of postpartum infections (including endometritis, urinary tract infection, mastitis, surgical site infection, and episiotomy site infection) and antimicrobial resistance of responsible pathogens

Limitations

Unable to perform clinical or microbiological testing of participants with chorioamnionitis in labour, puerperal sepsis, and thrombotic phlebitis
Prolonged rupture of membranes was not directly measured
Unable to confirm whether prescribed antibiotics were given or determine the timing of the prescription relative to the cesarean section procedure

Implication

Postpartum infections are highly prevalent in Ukraine, occurring in 28.1% of women, with the majority detected after hospital discharge and showing significant antimicrobial resistance.

Abstract

OBJECTIVE: Aim: To study the potential mechanisms of the beneficial cardiovascular effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, the possibilities of improving the treatment and prognosis of patients with acute heart failure (HF) during their use. PATIENTS AND METHODS: Materials and Methods: The data analysis of literary sources has been conducted regarding the results of existing studies evaluating the clinical benefit and safety of SGLT-2 inhibitors in patients with acute heart failure. CONCLUSION: Conclusions: The peculiarities of the pharmacological action of SGLT-2 inhibitors and the obtained research results expand the possibilities of using this group of drugs, demonstrating encouraging prospects in improving the prognosis of patients hospitalized with acute heart failure.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rоsul et al. (2024) conducted a cohort in Postpartum infections (n=21,968).

synapsesocial.com/papers/6a1c12bdea84844e355f67c9 https://doi.org/10.36740/wlek202403130

View Full Paper

Ask AI

Bookmark

Share

Expanding the possibilities of using sodium-glucose cotransporter 2 inhibitors in patients with heart failure

Study Design

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Expanding the possibilities of using sodium-glucose cotransporter 2 inhibitors in patients with heart failure

Study Design

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading